<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6477">
  <stage>Registered</stage>
  <submitdate>25/03/2010</submitdate>
  <approvaldate>25/03/2010</approvaldate>
  <nctid>NCT01094093</nctid>
  <trial_identification>
    <studytitle>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>20080767</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Psoriasis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AMG 139

Experimental: Part B - Four dose levels of AMG 139 administered as a single dose SC or IV in subjects with moderate-severe psoriasis (Part B).

Experimental: Part A - Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers.


Treatment: drugs: AMG 139
Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers (Part A) and subjects with moderate-severe psoriasis (Part B).

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety &amp; tolerability: treatment-emergent AEs including clinically significant changes in physical examinations, safety lab tests, ECG, vital signs, or immunogenicity to AMG 139</outcome>
      <timepoint>16-24 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Characterization of the pharmacokinetics (PK) of AMG 139</outcome>
      <timepoint>16-24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Psoriasis Activity and Severity Index (PASI) scores (Part B only)</outcome>
      <timepoint>16-24 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Part A - Healthy Volunteers:

          -  Healthy male or female of non-reproductive potential subjects between 18 to 45
             years-of-age

          -  Body mass index (BMI) between 18 and 32 kg/m2

          -  Normal or clinically acceptable physical examination, clinical laboratory values, and
             ECG

          -  Additional inclusion criteria apply

        Part B - Psoriasis Subjects:

          -  Male or female of non-reproductive potential subjects with PsO between 18 to 55
             years-of-age

          -  Body mass index (BMI) between 18 and 32 kg/m2

          -  Normal or clinically acceptable physical examination (PE), clinical laboratory values,
             and ECG; clinically acceptable PE includes evidence of moderate to severe plaque PsO

          -  Diagnosis of plaque PsO for at least 6 months

          -  Moderate to severe plaque PsO defined by:

          -  A minimum PASI score of = 10

          -  Psoriasis involving = 10% of the Body Surface Area (BSA)

          -  Additional inclusion criteria apply</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Parts A - Healthy Volunteers:

          -  History or evidence of a clinically significant disorder (including psychiatric),
             condition or disease that would pose a risk to subject safety or interfere with the
             study evaluation, procedures or completion;

          -  Recent or on-going infection(s)

          -  Underlying condition(s) that predisposes the subject to infections

          -  History of malignancy of any type, other than in situ cervical cancer or surgically
             excised non-melanomatous skin cancers in past 5 years

          -  Additional exclusion criteria apply

        Part B - Psoriasis Subjects:

          -  History or evidence of a clinically significant disorder (including psychiatric),
             condition or disease that would pose a risk to subject safety or interfere with the
             study evaluation, procedures or completion;

          -  Recent or on-going infection(s)

          -  Underlying condition(s) that predisposes the subject to infections

          -  Guttate, pustular, or other non-plaque forms of PsO

          -  Evidence of skin conditions other than PsO (eg, eczema) that would interfere with
             evaluations of the effect of investigational product on psoriasis

          -  History of malignancy of any type, other than in situ cervical cancer or surgically
             excised non-melanomatous skin cancers in past 5 years

          -  Additional exclusion criteria apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>11/04/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>73</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>26/07/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Nucleus Network Limited - Melbourne</hospital>
    <hospital>Clinical Medical and Analytical eXcellence (CMAX) - Adelaide</hospital>
    <hospital>QPharm Pty Limited - Herston</hospital>
    <postcode>3004 - Melbourne</postcode>
    <postcode>SA500 - Adelaide</postcode>
    <postcode>4006 - Herston</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Grafton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Allergan</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess the safety and tolerability of AMG 139 following
      single subcutaneous (SC) or intravenous (IV) dose administration in healthy subjects and
      subjects with moderate to severe psoriasis (PsO).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01094093</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Carl Gommoll, MS</name>
      <address>Allergan</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>